Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.

7502Background: In PACE (NCT01207440) heavily pretreated patients (pts) with chronic-phase CML (CP-CML) had deep, lasting responses to PON; long-term follow-up showed increasing rates of arterial o...